Skip to main content
. 2021 Feb 9;11:618428. doi: 10.3389/fimmu.2020.618428

Table 2.

HCMV ppp65 epitope category distribution in HCMV positive, HLA-A*02:01 positive subjects.

Test Subjects' CD8+ T Cells Specific for Epitopes
ID 1 ID 2 ID 3 ID 4 ID 5 ID 6 ID 7 ID 8 ID 9 ID 10
Cryptic Epitopes
Number 11 23 32 24 6 2 14 3 8 21
Cum. SFU 12.10 18.67 67.15 92.50 3.04 0.39 58.40 11.53 21.57 56.12
% of total SFU 1.02% 4.41% 3.02% 13.54% 0.73% 0.24% 4.03% 1.04% 2.89% 5.09%
Subdominant Epitopes
Number 14 8 5 17 6 2 6 0 1 16
Cum. SFU 45 35 63 230 14 21 194 0 7 132
% of total SFU 4% 8% 3% 34% 3% 13% 13% 0% 1% 12%
Dominant Epitopes
Number 15 4 3 4 9 0 3 1 0 5
Cum. SFU 281 72 147 193 263 0 178 73 0 221
% of total SFU 24% 17% 7% 28% 63% 0% 12% 7% 0% 20%
Super Dominant Epitopes
Number 3 1 4 2 1 1 3 2 2 3
Cum. SFU 847 298 1948 168 139 139 1019 1027 717 694
% of total SFU 71% 70% 88% 25% 33% 86% 70% 92% 96% 63%
Total Epitopes Recognized 43 36 44 47 22 5 26 6 11 45
Cumulative Spec. SFU 1185 424 2226 683 418 161 1450 1111 746 1103

The number of cryptic, subdominant, dominant and super-dominant epitopes, as defined in the text, are shown for the individual test subjects, along with the sum of epitopes in each category (Total Epitopes Recognized) for each PBMC donor. The absolute number of CD8+ T cells targeting peptides in each category (Cum. SFU) is also shown. From the number of all pp65-specific CD8+ T cells detected in each subject (Cumulative Spec. SFU) the percentage of CD8+ T cells targeting peptides in each of the four response categories has been calculated (% of total SFU). The SFU counts shown are after subtracting the mean + 3 SD specificity cut off value. Because SFU counts for the cryptic category frequently were at the cut-off value, or barely exceeded it, they shown with two decimal places.